endo-avoid-random-gh-diagnosis

name	endo-avoid-random-gh-diagnosis
description	Recommends against using random GH levels to diagnose acromegaly because of pulsatile secretion. Use when a clinician considers ordering a random GH test to evaluate for acromegaly in a patient with suggestive features.

Avoid random GH measurement for acromegaly diagnosis

STEP 1 — Gather Information

Collect clinical features suggestive of acromegaly (e.g., acral enlargement, facial changes, comorbidities such as diabetes, hypertension, sleep apnea, carpal tunnel syndrome) and determine if a random GH test is being considered for diagnosis.

STEP 2 — Rule In / Rule Out

If a random GH test is being considered to evaluate for acromegaly, proceed to step 3; otherwise, do not order random GH and end evaluation.

STEP 3 — Classify or Stratify

Classify the scenario as “random GH not recommended for diagnosis” per guideline recommendation against reliance on random GH levels.

STEP 4 — Decide

Do not order random GH; instead, order serum IGF-1 as the initial screening test for acromegaly.

Clinical Guardrails / Mimics / Pitfalls

Do not interpret random GH levels as diagnostic or use them to rule in/out acromegaly; avoid relying on single random GH due to pulsatile secretion; use IGF-1 and OGTT with glucose suppression for confirmation.

Concrete Clinical Example

A 48‑year‑old presents with shoe size increase, jaw protrusion, and fatigue; the clinician considers ordering a random GH test. Following the skill, they order IGF‑1 instead; an elevated IGF‑1 prompts an OGTT to assess GH suppression.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700